- Home
- GKOS vs UBER Comparison
GKOS vs UBER Comparison
Compare GKOS & UBER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- UBER
- Stock Information
- Founded
- GKOS 1998
- UBER 2009
- Country
- GKOS United States
- UBER United States
- Employees
- GKOS 995
- UBER N/A
- Industry
- GKOS Medical/Dental Instruments
- UBER Business Services
- Sector
- GKOS Health Care
- UBER Consumer Discretionary
- Exchange
- GKOS Nasdaq
- UBER Nasdaq
- Market Cap
- GKOS 5.1B
- UBER N/A
- IPO Year
- GKOS 2015
- UBER 2019
- Fundamental
- Price
- GKOS $90.26
- UBER $75.24
- Analyst Decision
- GKOS Strong Buy
- UBER Strong Buy
- Analyst Count
- GKOS 13
- UBER 32
- Target Price
- GKOS $155.00
- UBER $89.90
- AVG Volume (30 Days)
- GKOS 1.0M
- UBER 19.6M
- Earning Date
- GKOS 04-30-2025
- UBER 05-07-2025
- Dividend Yield
- GKOS N/A
- UBER N/A
- EPS Growth
- GKOS N/A
- UBER 422.12
- EPS
- GKOS N/A
- UBER 4.56
- Revenue
- GKOS $383,481,000.00
- UBER $43,978,000,000.00
- Revenue This Year
- GKOS $27.84
- UBER $16.78
- Revenue Next Year
- GKOS $27.99
- UBER $14.57
- P/E Ratio
- GKOS N/A
- UBER $16.50
- Revenue Growth
- GKOS 21.85
- UBER 17.96
- 52 Week Low
- GKOS $77.91
- UBER $54.84
- 52 Week High
- GKOS $163.71
- UBER $87.00
- Technical
- Relative Strength Index (RSI)
- GKOS 41.57
- UBER 56.05
- Support Level
- GKOS $86.16
- UBER $72.05
- Resistance Level
- GKOS $94.55
- UBER $73.40
- Average True Range (ATR)
- GKOS 6.54
- UBER 3.73
- MACD
- GKOS 1.11
- UBER 0.55
- Stochastic Oscillator
- GKOS 54.51
- UBER 95.62
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.